114 related articles for article (PubMed ID: 19632950)
1. Cancer treatments: can we find treasures at the bottom of the sea?
Provencio M; Sánchez A; Gasent J; Gómez P; Rosell R
Clin Lung Cancer; 2009 Jul; 10(4):295-300. PubMed ID: 19632950
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH
Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.
Brown AP; Morrissey RL; Faircloth GT; Levine BS
Cancer Chemother Pharmacol; 2002 Oct; 50(4):333-40. PubMed ID: 12357309
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and limitations in the application of kahalalides for the control of cancer.
Wyer S; Townsend DM; Ye Z; Kourtidis A; Choo YM; de Barros ALB; Donia MS; Hamann MT
Biomed Pharmacother; 2022 Apr; 148():112676. PubMed ID: 35149387
[TBL] [Abstract][Full Text] [Related]
5. An efficient and cost-effective approach to kahalalide F N-terminal modifications using a nuisance algal bloom of Bryopsis pennata.
Wang B; Waters AL; Valeriote FA; Hamann MT
Biochim Biophys Acta; 2015 Sep; 1850(9):1849-54. PubMed ID: 25964068
[TBL] [Abstract][Full Text] [Related]
6. Update on the role of topotecan in the treatment of non-small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
[TBL] [Abstract][Full Text] [Related]
7. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of kahalalide F synthetic analogues.
Jiménez JC; López-Macià A; Gracia C; Varón S; Carrascal M; Caba JM; Royo M; Francesch AM; Cuevas C; Giralt E; Albericio F
J Med Chem; 2008 Aug; 51(16):4920-31. PubMed ID: 18672864
[TBL] [Abstract][Full Text] [Related]
9. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.
Janmaat ML; Rodriguez JA; Jimeno J; Kruyt FA; Giaccone G
Mol Pharmacol; 2005 Aug; 68(2):502-10. PubMed ID: 15908515
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of kahalalide F in advanced cancer patients.
Miguel-Lillo B; Valenzuela B; Peris-Ribera JE; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2015 Aug; 76(2):365-74. PubMed ID: 26093949
[TBL] [Abstract][Full Text] [Related]
13. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents.
Cruz LJ; Luque-Ortega JR; Rivas L; Albericio F
Mol Pharm; 2009; 6(3):813-24. PubMed ID: 19317431
[TBL] [Abstract][Full Text] [Related]
14. Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Sparidans RW; Stokvis E; Jimeno JM; López-Lázaro L; Schellens JH; Beijnen JH
Anticancer Drugs; 2001 Aug; 12(7):575-82. PubMed ID: 11487713
[TBL] [Abstract][Full Text] [Related]
15. Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Nuijen B; Bouma M; Manada C; Jimeno JM; Lazaro LL; Bult A; Beijnen JH
Invest New Drugs; 2001; 19(4):273-81. PubMed ID: 11561686
[TBL] [Abstract][Full Text] [Related]
16. Maintenance chemotherapy for non-small-cell lung cancer.
Kim YH; Mishima M
Cancer Treat Rev; 2011 Nov; 37(7):505-10. PubMed ID: 21257270
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
18. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
